AUTL.US Autolus Therapeutics Ltd

Healthcare Biotechnology USA Stocks
1.17 USD
Close of Nov 13, 2026
1.12 2.58
Market cap
USD 311M
P/E
-
P/B
11.61x
ROE
-806.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AUTL.US undervalued?

Graham number

The Graham number of Autolus Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Autolus Therapeutics Ltd fundamental analysis

No fundamental analysis for Autolus Therapeutics Ltd yet.

Autolus Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Autolus Therapeutics Ltd

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multi…

Full company profile